TABLE 1.
Patient characteristics (n = 10)
| Year of transplantation | 2005–2014 | |
|---|---|---|
| Sex (M/F) | 7/3 | |
| Age, years | 39.7 ± 13.75 | |
| End‐stage heart failure etiology, n (%) | Ischemic cardiomyopathy | 3 (30%) |
| Dilated cardiomyopathy | 4 (40%) | |
| Post‐myocarditic cardiomyopathy | 1 (10%) | |
| Retransplant | 1 (10%) | |
| Postpartum cardiomyopathy | 1 (10%) | |
| Immunosuppressive regimen a | Induction ATG | |
| Maintenance | ||
| Csa + MMF + prednisone | ||
| Csa + azathioprine + prednisone | ||
| Tacrolimus + MMF + prednison | ||
|
Acute graft rejection episodes b , n (%) |
8 (80%) | |
| Mortality, n (%) | Squamous cell carcinoma, 1 (10%) | |
| Donor | Sex (M/F) | 6/4 |
| Age, year | 41.4 ± 15.67 | |
| Ischemia, min | 164.2 ± 72.51 | |
Abbreviations: ATG, thymoglobulin; Csa, cyclosporine; CVA, cerebrovascular accident; MMF, mycophenolate.
Data are expressed as mean ± SD.
a
Immunosuppressive regimen was subsequently tuned according to patient conditions.
bRequiring intravenous steroid treatment.